Prizlon-cel reaches US clinical development as AbelZeta rebuilds its large B-cell lymphoma strategy.
AbelZeta has regained global rights to dual CD19/CD20 CAR-T prizlon-cel and received FDA IND clearance, backed by early Chinese data reporting a 91.5% response rate.